


Garenoxacin mesylate

Cat. No.:	HY-17460B
CAS No.:	223652-82-2
Molecular Formula:	C ₂₄ H ₂₄ F ₂ N ₂ O ₇ S
Molecular Weight:	522.52
Target:	Bacterial; Topoisomerase
Pathway:	Anti-infection; Cell Cycle/DNA Damage
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Garenoxacin (BMS 284756) mesylate is an orally active quinolone antibiotic and Garenoxacin mesylate has a broad spectrum of activity against a wide array of gram-positive and gram-negative bacteria, anaerobes. Garenoxacin mesylate also inhibits Gyrase and TOPO IV ^{[1][2][3][4]} .
IC₅₀ & Target	1.25 µg/mL (Gyrase), 1.5-2.5 µg/mL (TOPO IV) ^[2]

REFERENCES

- [1]. Waites KB, et al. In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas. *Antimicrob Agents Chemother.* 2003 Jan;47(1):161-5.
- [2]. Ince D, et al. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone. *Antimicrob Agents Chemother.* 2002 Nov;46(11):3370-80.
- [3]. Zhao X, et al. Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother.* 2003 Mar;47(3):1023-7.
- [4]. Azoulay-Dupuis E, et al. Activities of garenoxacin against quinolone-resistant *Streptococcus pneumoniae* strains in vitro and in a mouse pneumonia model. *Antimicrob Agents Chemother.* 2004 Mar;48(3):765-73.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA